SUPN Supernus Pharmaceuticals
- 34.700
- +0.730+2.15%
- 37.000
- +2.300+6.63%
Supernus Pharmaceuticals所有资讯
Supernus Pharmaceuticals | SC 13G/A：超过5%持股股东披露文件(修正)-Macquarie Group Limited(4.78%),Macquarie Management Holdings Inc(4.78%)等
Supernus Pharmaceuticals | SC 13G：超过5%持股股东披露文件-Dimensional Fund Advisors LP(5.2%)
Supernus Pharmaceuticals | 4：持股变动声明-董事 GEMAYEL GEORGES
Supernus Pharmaceuticals | 4：持股变动声明-高管 Khattar Jack A.
Supernus Pharmaceuticals | 4：持股变动声明-高管 Khattar Jack A.
Supernus Pharmaceuticals | 4：持股变动声明-高管 Bhatt Padmanabh P.
Supernus Pharmaceuticals | 4：持股变动声明-高管 Bhatt Padmanabh P.
Supernus Pharmaceuticals | 4：持股变动声明-高管 Bhatt Padmanabh P.
Supernus Pharmaceuticals | 4：持股变动声明-高管 Bhatt Padmanabh P.
Supernus Pharmaceuticals | 4：持股变动声明-高管 Bhatt Padmanabh P.
Supernus Pharmaceuticals | 4：持股变动声明-高管 Bhatt Padmanabh P.
Supernus Pharmaceuticals | 4：持股变动声明-高管 Bhatt Padmanabh P.
Supernus Pharmaceuticals | 4：持股变动声明-高管 Khattar Jack A.
Supernus Pharmaceuticals | 4：持股变动声明-高管 Mottola Frank
Supernus Pharmaceuticals | 4：持股变动声明-高管 Bhatt Padmanabh P.
Supernus Pharmaceuticals | 4：持股变动声明-董事 GEMAYEL GEORGES
Supernus Pharmaceuticals | 4：持股变动声明-董事 SIEBERT JOHN M
Supernus Pharmaceuticals | 4：持股变动声明-董事 Hudson Frederick M.
Supernus Pharmaceuticals | 4：持股变动声明-董事 Barlow Carrolee
Supernus Pharmaceuticals | 4：持股变动声明-董事 NEWHALL CHARLES W III
分析
目标价预测
暂无数据
暂无数据